TXG 10x Genomics Corp Earnings per share for the last twelve months
Compliance with environmental standards in the production of 10x Genomics, Inc. (TXG) instruments remains formal. However, the business relies on the sale of expensive equipment and high-demand sequencing consumables. The TTM earnings per share clearly demonstrate these operational results, where the indicator value reaches -0.52. Such a model guarantees a steady cash flow through the regular replenishment of reagents in laboratories.
Metric breakdowns and analytics for 10x Genomics, Inc. (TXG)
- current quotes and average value forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Debt to Equity 10x Genomics, Inc.|TXG - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio 10x Genomics, Inc.|TXG - Aggregate Debt Obligations|Debts to Book Capitalization 10x Genomics|TXG - Long-Term Debt Volume|Company Short-Term Debt 10x Genomics|Quick Ratio 10xgenomics.com
- net income and valuation multiples indicators:
TXG - Net Income|Future Profit 10x Genomics, Inc.|TXG - Business Payback Period|Projected Price to Earnings 10x Genomics|TXG - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio 10x Genomics|TXG - Operating profit before amortization|Net earnings per share (EPS TTM) 10x Genomics|TXG - Net earnings per share for the trailing year|Quarterly EPS earnings growth 10xgenomics.com|TXG - Earnings per share growth this year|Net earnings per share growth forecast for next year 10x Genomics, Inc.
- total revenue and sales volume data:
General company analysis:10x Genomics Inc (TXG)
This indicator is calculated as the ratio of total net income over the last four quarters to the total number of shares outstanding, measuring the actual efficiency of income generation per share. Amid slowing equipment sales for 10x Genomics, Inc. (TXG), the current EPS TTM level serves as a critical marker of management's ability to convert innovation into profit, where a stagnating curve signals a risk of capital freeze.
Competitors of 10x Genomics, Inc.
TEM: Net earnings per share for the last 12 months|QGEN (Qiagen Group) - Earnings per share for the last 12 months|Ionis (IONS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Repligen Inc. (RGEN)|RNA (Avidity Biosciences) - Net earnings per share (EPS TTM)|CRSP (CRISPR Therapeutics AG) - Earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx (WGS)|RARE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics Inc)|Earnings per share for the trailing year SRPT|twistbioscience.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year NTLA (Intellia Therapeutics)|Stoke Therapeutics (STOK) - Earnings per share for the last twelve months|BioLife Corp (BLFS) - Net earnings per share (EPS TTM)|WVE (wavelifesciences.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Maze Therapeutics Inc|Net earnings per share (EPS TTM) SION|PRME - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TSHA (Taysha Corp)|Earnings per share for the trailing year QURE|MeiraGTx Holdings - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year REGENXBIO Corp (RGNX)|solidbio.com (SLDB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months OCGN|PACB (PacBio Corp) - Net earnings per share (EPS TTM)|BNTC: Earnings per share for the trailing year|Earnings per share for the last twelve months Design Corp (DSGN)|Net earnings per share for the last 12 months Rocket Pharmaceuticals Inc RCKT|FDMT: Net earnings per one share for the last twelve months|LXEO: Earnings per share for the last 12 months|Korro Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Editas Medicine|Silence Therapeutics (SLN) - Earnings per share for the last twelve months|PRQR (ProQR Therapeutics N.V.) - Earnings per share for the last twelve months|CDXS (Codexis Inc) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months sangamo.com (SGMO)|Net earnings per share (EPS TTM) NAUT|Net earnings per share (EPS TTM) Metagenomi (MGX)|Earnings per share for the last twelve months Precision BioSciences DTIL|Net earnings per share (EPS TTM) Generation Bio Corp GBIO|Boundless Bio, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Exicure Inc.|Imunon, Inc. (IMNN) - Earnings per share for the last twelve months|RXi Pharmaceuticals (PHIO) - Net earnings per share (EPS TTM)|MBIO (Mustang Bio Corp) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months RNAZ (TransCode Therapeutics)|Net earnings per share (EPS TTM) BNGO|APDN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) BLUE (bluebird bio Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies (IPA)|OMGA: Net earnings per share for the last 12 months|OMIC (Singular Genomics Systems Inc) - Earnings per share for the last 12 months|Regulus Therapeutics (RGLS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months syros.com (SYRS)|TBIO (Telesis Bio Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months TRACON Pharmaceuticals Inc. (TCON)|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)
